Seagen Inc.
- Country
- πΊπΈUnited States
- Ownership
- Public, Subsidiary
- Established
- 1998-01-01
- Employees
- 3.2K
- Market Cap
- -
- Website
- http://www.seagen.com
FDG-PET to Investigate SGN-15 and Docetaxel in Patients With Advanced Non-Small Cell Lung Carcinoma
- Conditions
- Non-Small Cell Lung Carcinoma
- First Posted Date
- 2004-07-02
- Last Posted Date
- 2011-10-24
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00086333
- Locations
- πΊπΈ
University of Chicago, Chicago, Illinois, United States
πΊπΈThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
πΊπΈProvidence Health System, Regional Cancer Program, Portland, Oregon, United States
Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma
- Conditions
- Anaplastic Large-Cell Lymphoma
- First Posted Date
- 2004-03-16
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT00079755
- Locations
- πΊπΈ
University of Alabama, Birmingham, Birmingham, Alabama, United States
πΊπΈUniversity of Califorinia at Los Angeles, Los Angeles, California, United States
πΊπΈGeorgetown University, Washington, District of Columbia, United States
Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Drug: SGN-40 (anti-huCD40 mAb)
- First Posted Date
- 2004-03-16
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT00079716
- Locations
- πΊπΈ
James R. Berenson M.D., Inc., West Hollywood, California, United States
πΊπΈRocky Mountain Cancer Center, Denver, Colorado, United States
πΊπΈDana Farber Cancer Institute, Boston, Massachusetts, United States
Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2003-06-27
- Last Posted Date
- 2011-10-24
- Lead Sponsor
- Seagen Inc.
- Registration Number
- NCT00028483
- Locations
- πΊπΈ
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies
- Conditions
- Hodgkin DiseaseLymphoma, Large-CellSarcoma, KaposiLymphoma, T-Cell, CutaneousLymphoma, B-Cell
- First Posted Date
- 2003-01-15
- Last Posted Date
- 2011-10-12
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT00051597
- Locations
- πΊπΈ
University of Alabama, Birmingham, Birmingham, Alabama, United States
πΊπΈUSC Norris Cancer Center, Los Angeles, California, United States
πΊπΈUniversity of Miami, Miami, Florida, United States
Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With Gemcitabine in Patients With Ovarian Cancer
- Conditions
- Ovarian Neoplasms
- First Posted Date
- 2003-01-15
- Last Posted Date
- 2011-10-24
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00051584
- Locations
- πΊπΈ
Arizona Cancer Center, Tucson, Arizona, United States
πΊπΈSharp Healthcare, San Diego, California, United States
πΊπΈCalifornia Hematology Oncology Medical Group, Torrance, California, United States
Safety/Efficacy Study of Immunoconjugate With Docetaxel in Non-small Cell Lung Carcinoma
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2003-01-15
- Last Posted Date
- 2011-10-24
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00051571
- Locations
- πΊπΈ
UCLA Medical Center, Los Angeles, California, United States
πΊπΈBendheim Cancer Center, Greenwich, Connecticut, United States
πΊπΈFlorida Cancer Specialists, Fort Myers, Florida, United States
Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer
- Conditions
- Prostatic Neoplasms
- First Posted Date
- 2002-02-28
- Last Posted Date
- 2011-10-24
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT00031187
- Locations
- πΊπΈ
Arizona Cancer Center, Tucson, Arizona, United States
πΊπΈHighlands Oncology Group, Springdale, Arkansas, United States
πΊπΈWest Los Angeles - VA Healthcare Center, Los Angeles, California, United States